First mAb Produced via Fully Continuous Biomanufacturing

07:00 EDT 24 Sep 2019 | Genetic Engineering News

BiosanaPharma received approval from the Australian Bellberry Human Research Ethics Committee to begin a Phase I clinical trial for a biosimilar version of omalizumab, the first monoclonal antibody (mAb) produced with a fully continuous biomanufacturing process. BiosanaPharma wants to make antibodies more accessible as therapeutics.

The post First mAb Produced via Fully Continuous Biomanufacturing appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: First mAb Produced via Fully Continuous Biomanufacturing


More From BioPortfolio on "First mAb Produced via Fully Continuous Biomanufacturing"

Quick Search

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...